

Welcome to Dermbits! Watch short videos of KOLs answering your questions
Topical Therapies
What documentation details helps support approval for ruxolitinib cream?
Featuring Alexandra Golant, MD
Topical Therapies
Can EHR templates improve access for new therapies like ruxolitinib?
Featuring Alexandra Golant, MD
Topical Therapies
What are common documentation mistakes that delay access to newer topicals?
Featuring Alexandra Golant, MD
Topical Therapies
What’s key to documenting steroid failure or intolerance clearly?
Featuring Alexandra Golant, MD
Topical Therapies
How do you talk to patients when access issues delay treatment?
Featuring Alexandra Golant, MD
Topical Therapies
What’s your top access tip for new clinicians balancing care and paperwork?
Featuring Alexandra Golant, MD
Cutaneous Melanoma
How does the MyPath Melanoma test differ from standard histopathologic evaluation?
Featuring Brent Moody, MD
Cutaneous Melanoma
When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?
Featuring Brent Moody, MD
Cutaneous Melanoma
What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?
Featuring Brent Moody, MD
Cutaneous Melanoma
How does a positive or negative MyPath Melanoma result impact your treatment recommendations?
Featuring Brent Moody, MD
Cutaneous Melanoma
What makes some melanocytic lesions difficult to diagnose based on histopathology alone?
Featuring Brent Moody, MD
Actinic Keratosis
When might you choose tirbanibulin over 5-FU for AK field therapy?
Featuring Vishal Patel, MD, FAAD, FACMS
48 of 900